TAT-NSF700scr

TAT-NSF700scr consists the intact TAT domain and glycine linker, followed by the NSF amino acids in a random order. TAT-NSF700scr is used as a control peptide that does not inhibit SNAREmediated exocytosis[1][2].

Product Specifications

UNSPSC

12352209

Target

HIV

Type

Peptides

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/tat-nsf700scr.html

Purity

95.17

Solubility

H2O : 23.81 mg/mL (adjust pH to 3 with 1 M HCl)

Smiles

O=C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(NCC(NCC(NCC(N[C@@H]([C@@H](C)CC)C(N1[C@@H](CCC1)C(N2[C@@H](CCC2)C(N[C@@H](C(C)C)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC5=CC=C(C=C5)O)N

Molecular Formula

C186H315N61O44

Molecular Weight

4109.87

References & Citations

[1]John W Calvert, et al. Inhibition of N-ethylmaleimide-sensitive factor protects against myocardial ischemia/reperfusion injury. Circ Res. 2007 Dec 7;101 (12) :1247-54.|[2]Mumtaz, et al. Acute and chronic adaptation of Supraoptic neurons to changes in osmolality. UNIVERSITY OFSASKATCHEWAN, 2011, 05.